Hummingbird’s dual ADC payloads deliver one-two punch to tumors

The ascendancy of antibody-drug conjugates as a therapeutic modality with broad utility in cancer has also revealed a major limitation of the tech — tumors often develop resistance to ADCs, leading to cancer progression.

The lightning-fast diversification of ADCs currently underway has put forward possible solutions, such as immune-stimulatory payloads meant to trigger a long-lasting antitumor immune response. The challenge with those approaches is to constrain the toxicity that results when the payload is released outside the tumor. ...